Fas ligand, death gene

Cell Death and Differentiation

Volumn 6, Issue 12, 1999, Pages 1174-1181

  Pinkoski, M J ^a   Green, D R ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Apoptosis; CD95 ligand; Gene regulation; Immune homeostasis and privilege

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN;

APOPTOSIS; GENE EXPRESSION REGULATION; PRIORITY JOURNAL; REVIEW; STRESS; T LYMPHOCYTE;

GOES;

EID: 0033401225     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400611     Document Type: Review

References (102)

1. Wyllie AH (1987) Apoptosis: cell death in tissue regulation. J. Pathol. 153: 313-316
2. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 28: 555-556
3. Wyllie AH and Morris RG (1982) Hormone-induced cell death. Purification ad properties of thymocytes undergoing apoptosis after glucocorticoid treatment. Am. J. Pathol. 109: 78-87
4. Wyllie AH, Morris RG, Smith AL and Dunlop D (1984) Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142: 67-77
5. Cohen JJ and Duke RC (1984) Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J. Immunol. 132: 38-42
6. Ucker DS (1987) Cytotoxic T lymphocytes and glucocorticoids activate an endogenous suicide process in target cells. Nature 327: 62-64
7. Martin SJ, Lennon SV, Bonham AM and Cotter TG (1990) Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J. Immunol. 145: 1859-1867
8. Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178
9. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S (1996) Fas ligand in human serum. Nature Med. 2: 317-322
10. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDMA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243
11. Nagata S (1997) Apoptosis by death factor. Cell 88: 355-365
12. Green DR (1998) Apoptotic pathways: the roads to ruin. Cell 94: 695-698
13. Ashkenazi A and Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305-1308
14. Thornberry NA and Lazebnik Y (1998) Caspases: enemies within. Science 281: 1312-1316
15. Wolf BB and Green DR (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem. 274: 20049-20052
16. Shi YF, Szalay MG, Paskar L, Sahai BM, Boyer M, Singh B, Green DR (1990) Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. J. Immunol. 144: 3326-3333
17. Shi YF, Sahai BM and Green DR (1989) Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes. Nature 339: 625-626
18. Ucker DS, Ashwell JD and Nickas G (1989) Activation-driven T cell death. I. Requirements for de novo transcription and translation and association with genome fragmentation. J. Immunol. 143: 3461-3469
19. Dhein J, Walczak H, Baumler C, Debatin KM and Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441
20. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR (1995) Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441-444
21. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A (1995) Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373: 444-448
22. Alderson MR, Tough TW, Davis-Smith T, Braddy S. Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181: 71-77
23. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH and Lenardo MJ (1995) Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351
24. Cohen PL and Eisenberg RA (1991 )Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9: 243-269
25. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317
26. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349
27. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976
28. Friesen C, Herr I, Krammer PH and Debatin KM (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2: 574-577
29. Reap EA, Roof K, Maynor K, Borrero M, Booker J and Cohen PL (1997) Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc. Natl. Acad. Sci. USA 94: 5750-5755
30. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A and Green DR (1998) DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol. Cell 1: 543-551
31. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME and Debatin KM (1998) Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 5: 884-893
32. Debatin KM, Suss D and Krammer PH (1994) Differential expression of APO-1 on human thymocytes: implications for negative selection? Eur. J. Immunol. 24: 753-758
33. Mogil RJ, Radvanyi L, Gonzalez-Quintial R, Miller R, Mills G, Theofilopoulos AN, Green DR (1995) Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int. Immunol. 7: 1451-1458
34. Adachi M, Suematsu S, Suda T, Watanabe D, Fukuyama H. Ogasawara J Tanaka T, Yoshida N, Nagata S (1996) Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc. Natl. Acad. Sci. USA 93: 2131-2136
35. Fleck M, Zhou T, Tatsuta T, Yang P, Wang Z and Mountz JD (1998) Fas/Fas ligand signaling during gestational Tcell development. J. Immunol. 160: 3766-3775
36. Kishimoto H, Surh CD and Sprent J (1998) A role for Fas in negative selection of thymocytes in vivo. J. Exp. Med. 187: 1427-1438
37. Kurasawa K, Hashimoto Y and Iwamoto I (1999) Fas Modulates both Positive and Negative Selection of Thymocytes. Cell. Immunol. 194: 127-135
38. Chinnaiyan AM, O'Rourke K, Tewari M and Dixit VM (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512
39. Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, Ng M, Wakeham A, Khoo W, Mitchell K, El-Deiry WS, Lowe SW, Goeddel DV, Mak TW (1998) FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279: 1954-1958
40. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM and Hedrick SM (1998) A role for FADD in T cell activation and development. Immunity 8: 439-449
41. Chang HY, Nishitoh H, Yang X, Ichijo H and Baltimore D (1998) Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281: 1860-1863
42. Chang HY, Yang X and Baltimore D (1999) Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation. Proc. Natl. Acad. Sci. USA 96: 1252-1256
43. Martin SJ (1993) Protein or RNA synthesis inhibition induces apoptosis of mature human CD4+ T cell blasts. Immunol. Lett. 35: 125-134
44. Tang D, Lahti JM, Grenet J and Kidd VJ (1999) Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism. J. Biol. Chem. 274: 7245-7252
45. Micheau O, Solary E, Hammann A and Dimanche-Boitrel MT (1999) Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274: 7987-7992
46. Rao A., Luo C and Hogan PG (1997) Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15: 707-747
47. Latinis KM, Norian LA, Eliason SL and Koretzky GA (1997) Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J. Biol. Chem. 272: 31427-31434
48. Baldwin Jr AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14: 649-683
49. Houghton JA, Harwood FG and Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc. Natl. Acad. Sci. USA 94: 8144-8149
50. Kasibhatla S, Genestier L and Green DR (1999) Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J. Biol. Chem. 274: 987-992
51. Norian LA, Latinis KM and Koretzky GA (1998) A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytes. J. Immunol. 161: 1078-1082
52. Mittelstadt PR and Ashwell JD (1998) Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression. Mol. Cell. Biol. 18: 3744-3751
53. Mittelstadt PR and Ashwell JD (1999) Role of Egr-2 in up-regulation of Fas ligand in normal T cells and aberrant double-negative lpr and gld T cells. J. Biol. Chem. 274: 3222-3227
54. Rincón M, Whitmarsh A, Yang DD, Weiss L, Derijard B, Jayaraj P, Davis RJ, Flavell RA (1998) The JNK pathway regulates the In vivo deletion of immature CD4(+)CD8(+) thymocytes. J. Exp. Med. 188: 1817-1830
55. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ and Flavell RA (1998) Defective T cell differentiation in the absence of Jnk1. Science 282: 2092-2095
56. Sabapathy K, Hu Y, Kallunki T, Schreiber M, David JP, Jochum W, Wagner EF, Karin M (1999) JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr. Biol. 9: 116-125
57. Faris M, Latinis KM, Kempiak SJ, Koretzky GA and Nel A (1998) Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol. Cell. Biol. 18: 5414-5424
58. Karin M, Liu Z and Zandi E (1997) AP-1 function and regulation. Curr. Opin. Cell. Biol. 9: 240-246
59. Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky GA, Nel A (1998) The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol. 160: 134-144
60. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR and Karin M (1999) Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19: 751-763
61. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128
62. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP and Green DR (1992) Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257: 212-214
63. Bissonnette RP, McGahon A, Mahboubi A and Green DR (1994) Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hyrbidomas. J. Exp. Med. 180: 2413-2418
64. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S and Evan GI (1997) Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278: 1305-1309
65. Genestier L, Kasibhatla S, Brunner T and Green DR (1999) Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189: 231-239
66. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868
67. Hillion J, Le Coniat M, Jonveaux P, Berger R and Bernard OA (1997) AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90: 3714-3719
68. Anderson MJ, Viars CS, Czekay S, Cavenee WK and Arden KC (1998) Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 47: 187-199
69. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321
70. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC (1999) Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284: 339-343
71. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA (1997) Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272: 31515-31524
72. Meier R, Alessi DR, Cron P, Andjelkovic M and Hemmings BA (1997) Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J. Biol. Chem. 272: 30491-30497
73. Rohn JL, Hueber AO, McCarthy NJ, Lyon D, Navarro P, Burgering BM, Evan GI (1998) The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis. Oncogene 17: 2811-2818
74. Darmon AJ, Pinkoski MJ and Bleackley RC (1999) Granule-mediated cytotoxicity. Results Probl. Cell Differ. 23: 103-125
75. Berke G (1995) PELs and the perform and granzyme independent mechanism of CTL-mediated lysis. Immunol. Rev. 146: 21-31
76. Berke G (1995) The CTL's kiss of death. Cell 81: 9-12
77. Pinkoski MJ, Hobman M, Heibein JA, Tomaselli K, Li F, Seth P, Froelich CJ, Bleackley RC (1998) Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. Blood 92: 1044-1054
78. Shi L, Mai S, Israels S, Browne K, Trapani JA and Greenberg AH (1997) Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J. Exp. Med. 185: 855-866
79. Berke G and Rosen D (1988) Highly lytic in vivo primed cytolytic T lymphocytes devoid of lytic granules and BLT-esterase activity acquire these constituents in the presence of T cell growth factors upon blast transformation in vitro. J. Immunol. 141: 1429-1436
80. Schick B and Berke G (1990) The lysis of cytotoxic T lymphocytes and their blasts by cytotoxic T lymphocytes. Immunology 71: 428-433
81. Berke G, Rosen D and Ronen D (1993) Mechanism of lymphocyte-mediated cytolysis: functional cytolytic T cells lacking perforin and granzymes. Immunology 78: 105-112
82. Helgason CD, Prendergast JA, Berke G and Bleackley RC (1992) Peritoneal exudate lymphocyte and mixed lymphocyte culture hybridomas are cytolytic in the absence of cytotoxic cell proteinases and perforin. Eur. J. Immunol. 22: 3187-3190
83. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305
84. Yonehara S, Ishii A and Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169: 1747-1756
85. Rouvier E, Luciani MF and Golstein P (1993) Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J. Exp. Med. 177: 195-200
86. Bossi G and Griffiths GM (1999) Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Med. 5: 90-96
87. Green DR and Ware CF (1997) Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA 94: 5986-5990
88. Ferguson TA and Griffith TS (1997) A vision of cell death: insights into immune privilege. Immunol. Rev. 156: 167-184
89. Griffith TS, Brunner T, Fletcher SM, Green DR and Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192
90. Griffith TS, Yu X, Herndon JM, Green DR and Ferguson TA (1996) CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5: 7-16
91. Chen JJ, Sun Y and Nabel GJ (1998) Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282: 1714-1717
92. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A and Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377: 630-632
93. Allison J, Georgiou HM, Strasser A and Vaux DL (1997) Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94: 3943-3947
94. Bonfoco E, Stuart PM, Brunner T, Lin T, Griffith TS, Gao Y, Nakajima H, Henkart PA, Ferguson TA, Green DR (1998) Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9: 711-720
95. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T, Debatin KM (1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19: 3809-3817
96. Sabelko-Downes KA, Cross AH and Russell JH (1999) Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189: 1195-1205
97. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366
98. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells a mechanism of immune evasion? Nature Med. 2: 1361-1366
99. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F (1999) The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20: 46-52
100. Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T and Matsuzawa A (1999) Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J. Immunol. 162: 7350-7357
101. Seino K, Kayagaki N, Takeda K, Fukao K, Okumura K and Yagita H (1997) Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 113: 1315-1322
102. Arai H, Gordon D, Nabel EG and Nabel GJ (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94: 13862-13367